Features
- Develops peptide-based therapies for degenerative diseases and tissue repair
- Targets damage from spinal cord injuries and strokes
- Supramolecular peptides that self-assemble into 3D nanostructures
- Nanostructures that mimic the extracellular matrix
- Activates cell receptors to promote regeneration signals
- Platform backed by 20+ years of research and 100+ peer-reviewed studies
Pricing Details
Amphix Bio does not use a traditional pricing model like software or digital platforms, because its activity consists of developing drugs and biotechnologies. Therefore, services are not sold directly to users, but rather treatments are developed within long-term research programs that are usually funded through investments and partnerships with pharmaceutical companies and research institutions. The company does not offer free plans or services open to the public, as its products are drugs and therapeutic technologies that are undergoing scientific development and testing before reaching the stage of medical use. There are no subscription plans or prices advertised to the public. The development of these treatments is usually funded through venture capital investments or collaborations with pharmaceutical companies and medical institutions, and the drug technologies may subsequently be licensed to other companies after passing the required clinical and regulatory stages.